Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have used “outdated information,” federal health officials said early Tuesday.
The Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data of the two-dose vaccine.
